Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Piper Sandler bullish on ViewRay as 1-year prostate data adds to data compendium » 15:01
06/23/20
06/23
15:01
06/23/20
15:01
VRAY

ViewRay

$2.03 /

-0.115 (-5.36%)

Piper Sandler analyst…

Piper Sandler analyst Jason Bednar notes that ViewRay announced the publication of one-year follow-up data to Amsterdam UMC's phase II prospective prostate study utilizing MRgRT. Early outcomes data was initially announced last August, and the one-year follow-up data shows a persistence of the strong initial data, including low to no toxicities, he adds. The analyst believes this follow-up data contributes to the growing body of clinical evidence supporting increased MRgRT use in a variety of tumors, ranging from what are ubiquitous and commonly treated cancers to those that are more challenging to treat. It's this growing body of superior clinical data that he expects to be critical to expanded reimbursement and corresponding therapy adoption over time. Bednar reiterates an Overweight rating on the shares with a $3.50 price target.

ShowHide Related Items >><<
VRAY ViewRay
$2.03 /

-0.115 (-5.36%)

VRAY ViewRay
$2.03 /

-0.115 (-5.36%)

06/16/20 Cantor Fitzgerald
ViewRay assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
ViewRay assumed with an Overweight at Cantor Fitzgerald
04/28/20 Guggenheim
ViewRay downgraded to Neutral on hospital budget strain at Guggenheim
04/28/20 Guggenheim
ViewRay downgraded to Neutral from Buy at Guggenheim
VRAY ViewRay
$2.03 /

-0.115 (-5.36%)

VRAY ViewRay
$2.03 /

-0.115 (-5.36%)

Hot Stocks
ViewRay announces publication of prospective phase II study of MRgRT » 08:11
06/23/20
06/23
08:11
06/23/20
08:11
VRAY

ViewRay

$2.15 /

-0.075 (-3.38%)

ViewRay announced the…

ViewRay announced the publication by the European Urology Oncology Journal of a prospective phase II study of MR-guided radiation therapy, or MRgRT, in patients with localized prostate cancer. The publication is a follow-up to early outcomes published in 2019 which reported low incidence of acute toxicity in both clinician- and patient-reported outcomes. The one-year data reported continued absence of grade 3 or higher toxicities and reductions in long-term patient-reported outcome measures after MRIdian treatment. Researchers from Amsterdam University Medical Centers enrolled 101 patients and the study is one of the first to research SBRT in a mix of intermediate- and high-risk prostate cancer patients, a population that is challenging to treat. The journal is the official scientific journal of the European Association of Urology.

ShowHide Related Items >><<
VRAY ViewRay
$2.15 /

-0.075 (-3.38%)

VRAY ViewRay
$2.15 /

-0.075 (-3.38%)

06/16/20 Cantor Fitzgerald
ViewRay assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
ViewRay assumed with an Overweight at Cantor Fitzgerald
04/28/20 Guggenheim
ViewRay downgraded to Neutral on hospital budget strain at Guggenheim
04/28/20 Guggenheim
ViewRay downgraded to Neutral from Buy at Guggenheim
VRAY ViewRay
$2.15 /

-0.075 (-3.38%)

VRAY ViewRay
$2.15 /

-0.075 (-3.38%)

Initiation
ViewRay assumed with an Overweight at Cantor Fitzgerald » 06:42
06/16/20
06/16
06:42
06/16/20
06:42
VRAY

ViewRay

$2.18 /

-0.045 (-2.03%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Brandon Folkes assumed coverage of ViewRay with an Overweight rating and $3 price target. The analyst believes hospital capital expenditure budgets will likely be constrained in 2020 and 2021 as they work through the complexities created by COVID, but thinks MRIdian offers significant advantages over the competition and believes ViewRay has the potential to drive increased usage within its installed base while hospital budgets, and new orders, remain constrained.

ShowHide Related Items >><<
VRAY ViewRay
$2.18 /

-0.045 (-2.03%)

VRAY ViewRay
$2.18 /

-0.045 (-2.03%)

06/15/20 Cantor Fitzgerald
ViewRay assumed with an Overweight at Cantor Fitzgerald
04/28/20 Guggenheim
ViewRay downgraded to Neutral on hospital budget strain at Guggenheim
04/28/20 Guggenheim
ViewRay downgraded to Neutral from Buy at Guggenheim
04/07/20 Piper Sandler
ViewRay should be owned for 'best-in-class' technology, says Piper Sandler
VRAY ViewRay
$2.18 /

-0.045 (-2.03%)

VRAY ViewRay
$2.18 /

-0.045 (-2.03%)

Initiation
ViewRay assumed with an Overweight at Cantor Fitzgerald » 16:17
06/15/20
06/15
16:17
06/15/20
16:17
VRAY

ViewRay

$2.18 /

-0.045 (-2.03%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Brandon Folkes assumed coverage of ViewRay with an Overweight rating and $3 price target.

ShowHide Related Items >><<
VRAY ViewRay
$2.18 /

-0.045 (-2.03%)

VRAY ViewRay
$2.18 /

-0.045 (-2.03%)

04/28/20 Guggenheim
ViewRay downgraded to Neutral on hospital budget strain at Guggenheim
04/28/20 Guggenheim
ViewRay downgraded to Neutral from Buy at Guggenheim
04/07/20 Piper Sandler
ViewRay should be owned for 'best-in-class' technology, says Piper Sandler
03/27/20 Morgan Stanley
ViewRay downgraded to Underweight with $2 target at Morgan Stanley
VRAY ViewRay
$2.18 /

-0.045 (-2.03%)

VRAY ViewRay
$2.18 /

-0.045 (-2.03%)

Over a month ago
Hot Stocks
ViewRay: Providence Portland Medical Center begins treatment with MRIdian Linac » 06:40
05/27/20
05/27
06:40
05/27/20
06:40
VRAY

ViewRay

$1.76 /

-0.055 (-3.04%)

ViewRay announced that…

ViewRay announced that Providence Portland Medical Center in Portland, Oregon has begun patient treatments with the MRIdian MR-Guided Therapy System. ViewRay said in a release, "The MRIdian system at Providence Portland Medical Center is part of The Elsie Franz Finley Radiation Oncology Center and Providence Cancer Institute. MRIdian utilizes on-table soft tissue imaging to allow oncologists to visualize, adapt and target using diagnostic-quality anatomical detail that is unavailable with conventional image-guided radiation therapy, or IGRT, technologies."

ShowHide Related Items >><<
VRAY ViewRay
$1.76 /

-0.055 (-3.04%)

VRAY ViewRay
$1.76 /

-0.055 (-3.04%)

04/28/20 Guggenheim
ViewRay downgraded to Neutral on hospital budget strain at Guggenheim
04/28/20 Guggenheim
ViewRay downgraded to Neutral from Buy at Guggenheim
04/07/20 Piper Sandler
ViewRay should be owned for 'best-in-class' technology, says Piper Sandler
03/27/20 Morgan Stanley
ViewRay downgraded to Underweight with $2 target at Morgan Stanley
VRAY ViewRay
$1.76 /

-0.055 (-3.04%)

VRAY ViewRay
$1.76 /

-0.055 (-3.04%)

Hot Stocks
ViewRay names Zach Stassen as CFO » 16:16
04/30/20
04/30
16:16
04/30/20
16:16
VRAY

ViewRay

$2.08 /

+0.15 (+7.77%)

ViewRay has named Zach…

ViewRay has named Zach Stassen as CFO, effective May 18. Stassen most recently served as CFO and CPP for Bolder Surgical, a privately held company that develops and markets laparoscopic surgical devices.

ShowHide Related Items >><<
VRAY ViewRay
$2.08 /

+0.15 (+7.77%)

04/28/20 Guggenheim
ViewRay downgraded to Neutral on hospital budget strain at Guggenheim
04/28/20 Guggenheim
ViewRay downgraded to Neutral from Buy at Guggenheim
04/07/20 Piper Sandler
ViewRay should be owned for 'best-in-class' technology, says Piper Sandler
03/27/20 Morgan Stanley
ViewRay downgraded to Underweight with $2 target at Morgan Stanley
Earnings
ViewRay withdraws 2020 guidance  16:15
04/30/20
04/30
16:15
04/30/20
16:15
VRAY

ViewRay

$2.08 /

+0.15 (+7.77%)

 
ShowHide Related Items >><<
VRAY ViewRay
$2.08 /

+0.15 (+7.77%)

04/28/20 Guggenheim
ViewRay downgraded to Neutral on hospital budget strain at Guggenheim
04/28/20 Guggenheim
ViewRay downgraded to Neutral from Buy at Guggenheim
04/07/20 Piper Sandler
ViewRay should be owned for 'best-in-class' technology, says Piper Sandler
03/27/20 Morgan Stanley
ViewRay downgraded to Underweight with $2 target at Morgan Stanley
Earnings
ViewRay reports Q1 EPS (19c), consensus (18c) » 16:15
04/30/20
04/30
16:15
04/30/20
16:15
VRAY

ViewRay

$2.08 /

+0.15 (+7.77%)

Reports Q1 revenue…

Reports Q1 revenue $14.3M, consensus $12.55M. "As we manage in this challenging environment, we are focused on what we can control. Value creation lies in driving our clinical, innovation and commercial pipeline while enhancing efforts to conserve capital," said CEO Scott Drake.

ShowHide Related Items >><<
VRAY ViewRay
$2.08 /

+0.15 (+7.77%)

04/28/20 Guggenheim
ViewRay downgraded to Neutral on hospital budget strain at Guggenheim
04/28/20 Guggenheim
ViewRay downgraded to Neutral from Buy at Guggenheim
04/07/20 Piper Sandler
ViewRay should be owned for 'best-in-class' technology, says Piper Sandler
03/27/20 Morgan Stanley
ViewRay downgraded to Underweight with $2 target at Morgan Stanley
Downgrade
ViewRay downgraded to Neutral on hospital budget strain at Guggenheim » 09:21
04/28/20
04/28
09:21
04/28/20
09:21
VRAY

ViewRay

$1.98 /

-0.215 (-9.79%)

Guggenheim analyst Chris…

Guggenheim analyst Chris Pasquale downgraded ViewRay to Neutral from Buy without a price target. The company's MRIdian system represents a "significant leap forward" in radiation therapy technology but its clinical value has not translated into meaningful commercial traction to date, Pasquale tells investors in a research note. The analyst, who remains optimistic about MRIdian's long-term potential, believes the strain being put on hospital budgets by the COVID-19 pandemic "further complicates" an already challenging near-term outlook for ViewRay.

ShowHide Related Items >><<
VRAY ViewRay
$1.98 /

-0.215 (-9.79%)

04/28/20 Guggenheim
ViewRay downgraded to Neutral from Buy at Guggenheim
04/07/20 Piper Sandler
ViewRay should be owned for 'best-in-class' technology, says Piper Sandler
03/27/20 Morgan Stanley
ViewRay downgraded to Underweight with $2 target at Morgan Stanley
03/27/20 Morgan Stanley
ViewRay downgraded to Underweight from Equal Weight at Morgan Stanley
Downgrade
ViewRay downgraded to Neutral from Buy at Guggenheim » 06:10
04/28/20
04/28
06:10
04/28/20
06:10
VRAY

ViewRay

$1.98 /

-0.215 (-9.79%)

Guggenheim analyst Chris…

Guggenheim analyst Chris Pasquale downgraded ViewRay to Neutral from Buy.

ShowHide Related Items >><<
VRAY ViewRay
$1.98 /

-0.215 (-9.79%)

04/07/20 Piper Sandler
ViewRay should be owned for 'best-in-class' technology, says Piper Sandler
03/27/20 Morgan Stanley
ViewRay downgraded to Underweight with $2 target at Morgan Stanley
03/27/20 Morgan Stanley
ViewRay downgraded to Underweight from Equal Weight at Morgan Stanley
03/13/20 BTIG
ViewRay downgraded to Neutral from Buy at BTIG

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.